Altarescu G - Search Results

1

Somatosensory evoked potentials as a marker of disease burden in type 3 Gaucher disease.

Garvey MA, Toro C, Goldstein S, Altarescu G, Wiggs EA, Hallett M, Schiffmann R. Garvey MA, et al. Among authors: altarescu g. Neurology. 2001 Feb 13;56(3):391-4. doi: 10.1212/wnl.56.3.391. Neurology. 2001. PMID: 11171908

2

Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease.

Moore DF, Altarescu G, Herscovitch P, Schiffmann R. Moore DF, et al. Among authors: altarescu g. BMC Neurol. 2002 Jun 18;2:4. doi: 10.1186/1471-2377-2-4. BMC Neurol. 2002. PMID: 12079501 Free PMC article. Clinical Trial.

3

Mucolipidosis type IV: characteristic MRI findings.

Frei KP, Patronas NJ, Crutchfield KE, Altarescu G, Schiffmann R. Frei KP, et al. Among authors: altarescu g. Neurology. 1998 Aug;51(2):565-9. doi: 10.1212/wnl.51.2.565. Neurology. 1998. PMID: 9710036

4

Profile of endothelial and leukocyte activation in Fabry patients.

DeGraba T, Azhar S, Dignat-George F, Brown E, Boutière B, Altarescu G, McCarron R, Schiffmann R. DeGraba T, et al. Among authors: altarescu g. Ann Neurol. 2000 Feb;47(2):229-33. Ann Neurol. 2000. PMID: 10665494

5

Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.

Altarescu G, Schiffmann R, Parker CC, Moore DF, Kreps C, Brady RO, Barton NW. Altarescu G, et al. Blood Cells Mol Dis. 2000 Aug;26(4):285-90. doi: 10.1006/bcmd.2000.0310. Blood Cells Mol Dis. 2000. PMID: 11042029 Clinical Trial.

6

The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease.

Altarescu G, Hill S, Wiggs E, Jeffries N, Kreps C, Parker CC, Brady RO, Barton NW, Schiffmann R. Altarescu G, et al. J Pediatr. 2001 Apr;138(4):539-47. doi: 10.1067/mpd.2001.112171. J Pediatr. 2001. PMID: 11295718

7

The neurogenetics of mucolipidosis type IV.

Altarescu G, Sun M, Moore DF, Smith JA, Wiggs EA, Solomon BI, Patronas NJ, Frei KP, Gupta S, Kaneski CR, Quarrell OW, Slaugenhaupt SA, Goldin E, Schiffmann R. Altarescu G, et al. Neurology. 2002 Aug 13;59(3):306-13. doi: 10.1212/wnl.59.3.306. Neurology. 2002. PMID: 12182165

8

Effect of genetic modifiers on cerebral lesions in Fabry disease.

Altarescu G, Moore DF, Schiffmann R. Altarescu G, et al. Neurology. 2005 Jun 28;64(12):2148-50. doi: 10.1212/01.WNL.0000166000.24321.4F. Neurology. 2005. PMID: 15985593

9

Enhanced endothelium-dependent vasodilation in Fabry disease.

Altarescu G, Moore DF, Pursley R, Campia U, Goldstein S, Bryant M, Panza JA, Schiffmann R. Altarescu G, et al. Stroke. 2001 Jul;32(7):1559-62. doi: 10.1161/01.str.32.7.1559. Stroke. 2001. PMID: 11441201 Free PMC article.

10

Cutaneous silent periods in patients with Fabry disease.

Syed NA, Sandbrink F, Luciano CA, Altarescu G, Weibel T, Schiffmann R, Floeter MK. Syed NA, et al. Among authors: altarescu g. Muscle Nerve. 2000 Aug;23(8):1179-86. doi: 10.1002/1097-4598(200008)23:8<1179::aid-mus4>3.0.co;2-7. Muscle Nerve. 2000. PMID: 10918253

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

130 results

Search Page

Filters